DK2442832T3 - Sammensætninger og fremgangsmåder til behandling af dissemineret sclerose - Google Patents
Sammensætninger og fremgangsmåder til behandling af dissemineret scleroseInfo
- Publication number
- DK2442832T3 DK2442832T3 DK10789788.6T DK10789788T DK2442832T3 DK 2442832 T3 DK2442832 T3 DK 2442832T3 DK 10789788 T DK10789788 T DK 10789788T DK 2442832 T3 DK2442832 T3 DK 2442832T3
- Authority
- DK
- Denmark
- Prior art keywords
- compositions
- methods
- disseminated sclerosis
- treating disseminated
- treating
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title 1
- 201000006417 multiple sclerosis Diseases 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/05—Dipeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06008—Dipeptides with the first amino acid being neutral
- C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
- C07K5/06026—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atom, i.e. Gly or Ala
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Genetics & Genomics (AREA)
- Gastroenterology & Hepatology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Immunology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Molecular Biology (AREA)
- General Chemical & Material Sciences (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Fodder In General (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Photographic Developing Apparatuses (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| NZ577731A NZ577731A (en) | 2009-06-16 | 2009-06-16 | Compositions and methods for treatment of multiple sclerosis |
| PCT/NZ2010/000112 WO2010147484A1 (en) | 2009-06-16 | 2010-06-16 | Compositions and methods for treatment of multiple sclerosis |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK2442832T3 true DK2442832T3 (da) | 2014-11-10 |
Family
ID=42646236
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK10789788.6T DK2442832T3 (da) | 2009-06-16 | 2010-06-16 | Sammensætninger og fremgangsmåder til behandling af dissemineret sclerose |
Country Status (20)
| Country | Link |
|---|---|
| US (1) | US8389479B2 (enExample) |
| EP (1) | EP2442832B1 (enExample) |
| JP (1) | JP5646617B2 (enExample) |
| CN (1) | CN102458476B (enExample) |
| AU (1) | AU2010260585B2 (enExample) |
| BR (1) | BRPI1009606A2 (enExample) |
| CA (1) | CA2688766C (enExample) |
| CY (1) | CY1115714T1 (enExample) |
| DK (1) | DK2442832T3 (enExample) |
| ES (1) | ES2521565T3 (enExample) |
| HR (1) | HRP20141035T1 (enExample) |
| IL (1) | IL216993A (enExample) |
| IN (1) | IN2012DN00167A (enExample) |
| MX (1) | MX2011013661A (enExample) |
| NZ (1) | NZ577731A (enExample) |
| PL (1) | PL2442832T3 (enExample) |
| PT (1) | PT2442832E (enExample) |
| SI (1) | SI2442832T1 (enExample) |
| SM (1) | SMT201400165B (enExample) |
| WO (1) | WO2010147484A1 (enExample) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2719252C (en) * | 2008-04-01 | 2016-01-19 | Innate Therapeutics Limited | Anti-infective agents comprising muramyl dipeptide microparticles and uses thereof |
| JP5847188B2 (ja) | 2010-10-25 | 2016-01-20 | バイオジェン・エムエイ・インコーポレイテッドＢｉｏｇｅｎ ＭＡ Ｉｎｃ． | ｓＶＣＡＭおよび／またはｓＭＡｄＣＡＭレベルの差を関連付けることにより、アルファ−４インテグリン活性の差を決定するための方法 |
| UY35790A (es) * | 2013-10-21 | 2015-05-29 | Teva Pharma | Marcadores genéticos que predicen la respuesta al acetato de glatiramer |
| CA2926507A1 (en) * | 2015-10-06 | 2017-04-06 | Innate Immunotherapeutics Limited | Compositions and methods for protection and/or repair of the nervous system |
| WO2017059486A1 (en) * | 2015-10-06 | 2017-04-13 | Innate Immunotherapeutics Limited | Compositions and methods for the treatment of epilepsy |
| WO2017070731A1 (en) * | 2015-10-28 | 2017-05-04 | Innate Immunotherapeutics Limited | Compositions and methods for the treatment of alzheimer's disease |
| US12097292B2 (en) | 2016-08-28 | 2024-09-24 | Mapi Pharma Ltd. | Process for preparing microparticles containing glatiramer acetate |
| HRP20250396T1 (hr) | 2016-08-31 | 2025-05-23 | Mapi Pharma Ltd. | Depo sustavi koji sadrže glatiramer acetat |
| AU2018242998B2 (en) | 2017-03-26 | 2023-11-02 | Mapi Pharma Ltd. | Glatiramer depot systems for treating progressive forms of multiple sclerosis |
| CA3099946A1 (en) * | 2018-05-18 | 2019-11-21 | Universite Laval | Use of nod2 agonist for the treatment, prophylaxis and/or delay of the onset of multiple sclerosis and alzheimer's disease |
| US12109271B2 (en) | 2018-07-03 | 2024-10-08 | University Of Florida Research Foundation, Incorporated | Microparticle systems and their use for the treatment of multiple sclerosis |
| US20230190570A1 (en) * | 2020-06-22 | 2023-06-22 | Otivio As | Methods for treating spasticity using anti-spasmodic compositions and negative pressure therapy |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2268372C (en) * | 1996-10-10 | 2012-11-27 | Probe International | Compositions and methods for treating viral infections |
| BRPI0512921A (pt) * | 2004-07-01 | 2008-04-22 | Den Kgl Veterinaer Og Landboho | processo para tratamento e profilaxia de ms |
| US8603978B2 (en) * | 2006-12-01 | 2013-12-10 | The United States of America, as represented by the Secretary, Department of Health and Humand Services | Use of muramyl dipeptide (MDP) for treating inflammation |
| JP2008251608A (ja) | 2007-03-29 | 2008-10-16 | Casio Comput Co Ltd | 半導体装置およびその製造方法 |
| WO2008150181A1 (en) | 2007-06-05 | 2008-12-11 | Innate Therapeutics Limited | Compositions and methods for treating anthrax exposure associated conditions |
| WO2008150182A1 (en) | 2007-06-05 | 2008-12-11 | Innate Therapeutics Limited | Compositions and methods for treatment of anthrax |
-
2009
- 2009-06-16 NZ NZ577731A patent/NZ577731A/en not_active IP Right Cessation
- 2009-12-16 US US12/639,733 patent/US8389479B2/en not_active Expired - Fee Related
- 2009-12-17 CA CA2688766A patent/CA2688766C/en not_active Expired - Fee Related
-
2010
- 2010-01-16 CN CN201080026791.5A patent/CN102458476B/zh not_active Expired - Fee Related
- 2010-01-16 BR BRPI1009606A patent/BRPI1009606A2/pt not_active Application Discontinuation
- 2010-06-16 HR HRP20141035AT patent/HRP20141035T1/hr unknown
- 2010-06-16 PL PL10789788T patent/PL2442832T3/pl unknown
- 2010-06-16 JP JP2012516022A patent/JP5646617B2/ja not_active Expired - Fee Related
- 2010-06-16 DK DK10789788.6T patent/DK2442832T3/da active
- 2010-06-16 SI SI201030779T patent/SI2442832T1/sl unknown
- 2010-06-16 IN IN167DEN2012 patent/IN2012DN00167A/en unknown
- 2010-06-16 AU AU2010260585A patent/AU2010260585B2/en not_active Ceased
- 2010-06-16 MX MX2011013661A patent/MX2011013661A/es active IP Right Grant
- 2010-06-16 ES ES10789788.6T patent/ES2521565T3/es active Active
- 2010-06-16 WO PCT/NZ2010/000112 patent/WO2010147484A1/en not_active Ceased
- 2010-06-16 EP EP10789788.6A patent/EP2442832B1/en active Active
- 2010-06-16 PT PT107897886T patent/PT2442832E/pt unknown
-
2011
- 2011-12-15 IL IL216993A patent/IL216993A/en not_active IP Right Cessation
-
2014
- 2014-11-03 CY CY20141100908T patent/CY1115714T1/el unknown
- 2014-11-04 SM SM201400165T patent/SMT201400165B/xx unknown
Also Published As
| Publication number | Publication date |
|---|---|
| BRPI1009606A2 (pt) | 2016-10-11 |
| PL2442832T3 (pl) | 2015-01-30 |
| EP2442832A1 (en) | 2012-04-25 |
| IL216993A (en) | 2016-03-31 |
| JP2012530132A (ja) | 2012-11-29 |
| JP5646617B2 (ja) | 2014-12-24 |
| IN2012DN00167A (enExample) | 2015-04-17 |
| AU2010260585A8 (en) | 2012-06-14 |
| US20100317589A1 (en) | 2010-12-16 |
| CN102458476B (zh) | 2014-08-20 |
| ES2521565T3 (es) | 2014-11-12 |
| HK1167101A1 (en) | 2013-02-01 |
| NZ577731A (en) | 2010-08-27 |
| EP2442832B1 (en) | 2014-08-06 |
| IL216993A0 (en) | 2012-02-29 |
| SI2442832T1 (sl) | 2014-12-31 |
| PT2442832E (pt) | 2014-11-11 |
| AU2010260585B2 (en) | 2013-02-21 |
| WO2010147484A8 (en) | 2012-07-19 |
| EP2442832A4 (en) | 2013-07-03 |
| MX2011013661A (es) | 2012-05-22 |
| CY1115714T1 (el) | 2017-01-25 |
| HRP20141035T1 (hr) | 2014-12-19 |
| WO2010147484A1 (en) | 2010-12-23 |
| SMT201400165B (it) | 2015-01-15 |
| CA2688766C (en) | 2015-06-30 |
| US8389479B2 (en) | 2013-03-05 |
| CN102458476A (zh) | 2012-05-16 |
| CA2688766A1 (en) | 2010-12-16 |
| AU2010260585A1 (en) | 2012-01-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK2442832T3 (da) | Sammensætninger og fremgangsmåder til behandling af dissemineret sclerose | |
| DK2894165T5 (da) | Fremgangsmåder og sammensætninger til behandling af komplementforbundne forstyrrelser | |
| DK2470656T3 (da) | Sammensætning til hæmning af genekspression og anvendelser heraf | |
| DK2565193T3 (da) | Sammensætninger og fremgangsmåder til hæmning af JAK-signalvejen | |
| DK2323638T3 (da) | Sammensætninger og fremgangsmåder til behandling af osteoartritis | |
| DK2766483T3 (da) | Fremgangsmåder og sammensætninger til screening for og behandling af udviklingsforstyrrelser | |
| DK3091034T3 (da) | Anti-CD40-antistoffer og anvendelser deraf | |
| DK2429574T3 (da) | Sammensætninger og fremgangsmåder til behandling af hæmatologiske cancere der targeterer sirp-cd47-interaktionen | |
| FR2941462B1 (fr) | Composition decapante | |
| DK2655370T3 (da) | Sammensætninger og fremgangsmåder til modulering af FXR-receptorer | |
| DK3311823T3 (da) | Fremgangsmåder og sammensætninger til brydning af biofilm ved hjælp af chitosan-derivatsammensætninger | |
| DK2293816T3 (da) | Fremgangsmåder til behandling af reumatoid arthritis | |
| DK2776567T3 (da) | Sammensætninger og fremgangsmåder til behandling af cytomegalovirus. | |
| DK3795573T3 (da) | Bestemte triazolopyraziner, sammensætninger deraf og fremgangsmåder til anvendelse deraf | |
| DK2593131T3 (da) | Fremgangsmåder og sammensætninger til cns-levering af iduronat-2-sulfatase | |
| DK2446090T3 (da) | Indretning og fremgangsmåde til reducering af støj | |
| DK3875104T3 (da) | Sammensætninger til behandling af ineffektiv erytropoiese | |
| DK2419732T3 (da) | Prionfrie nanopartikelsammensætninger og fremgangsmåder | |
| DK3128014T3 (da) | Midler og fremgangsmåder til sterilisering af biofunktionelle sammensætninger | |
| DK2361090T3 (da) | Sammensætninger til behandling af centralt medieret kvalme og opkastning | |
| DK3272342T3 (da) | Fremgangsmåder og sammensætninger til behandling af opmærksomhedsforstyrrelse | |
| DK2598500T3 (da) | Sammensætninger og fremgangsmåder til hæmning af jak-reaktionsvejen | |
| DK2593463T3 (da) | Formuleringer af rifaximin og anvendelser deraf | |
| DK2768321T3 (da) | Fremgangsmåder og sammensætninger til induktion af mæthed | |
| DK2552484T3 (da) | Fremgangsmåder og sammensætninger til reducering af parathyroidniveauer |